Pain control in burn injuries and their treatment remains a difficult challenge. Opioid therapy, although often used, has several limitations. An alternative to meet such demand is the application of local anesthetics, which are potential drugs for the treatment of such injuries. Bupivacaine is the local anesthetic most used worldwide in surgeries and postoperative periods, with a time of action of up to 6 hours. However, this time of action is not enough for the burning pain treatment, requiring the anesthetic to be applied several times a day, what may enhance its systemic toxicity. Drug-delivery carriers such as nanostructured lipid carriers (CLN) can overcome such limitations. The present project proposes the evaluation of cytotoxicity and in vivo anesthetic effect of optimized CLN formulations, composed of functional natural excipients (beeswax, lavender and melaleuca essential oils). Such CLNs were prepared for the encapsulation of bupivacaine (1%) in its enantiomeric-excess form: S75:R25. The samples will be evaluated regarding the in vitro cytotoxicity - over 3T3 and HCAT cells - and anesthetic effect in mice, trough the tail flick test. We propose, therefore, to perform in vitro and in vivo tests necessary for the development of these innovative anesthetic formulations.
News published in Agência FAPESP Newsletter about the scholarship: